Steve O'Loughlin

This profile gathers the share dealings of Steve O'Loughlin in Actinium Pharmaceuticals, Inc. Between 15 June 2017 and 10 December 2018, the trades on record add up to 4 filings.

Purchases make up the whole of the open-market record (3 purchases, €13k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2018, the count stands at 2 purchases and no sales.

Half of the purchases are above €3,815 and half below. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 3 purchases show a median change of +11.5%, with the price up in 67% of them. Past outcomes like these are no guarantee of what comes next.

Most recently, on 10 December 2018, the filings show an open-market purchase worth €3,815 in Actinium Pharmaceuticals, Inc. Publication is fast: at least half of the trades appear on SEC (Form 4) on the same day. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.